Armstrong Pharmaceuticals Inc. expects to relaunch its Primatene Mist asthma inhaler no earlier than 2013, two years after the firm initially planned to have a reformulated product ready and at least a year since the only OTC epinephrine inhaler was pulled from the market.
Armstrong’s parent firm, AmphastarPharmaceuticals Inc., July 18 announced it would submit a new drug application, without chlorofluorocarbon as a propellant...